Regulation of cocaine reward by CREB

Science

Volumn 282, Issue 5397, 1998, Pages 2272-2275

  Carlezon Jr , William A ^a   Thome, Johannes ^a   Olson, Valerie G ^a   Lane Ladd, Sarah B ^a   Brodkin, Edward S ^a   Hiroi, Noboru ^a   Duman, Ronald S ^a   Neve, Rachael L ^b   Nestler, Eric J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DYNORPHIN; KAPPA OPIATE RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RESPONSE; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; COCAINE; CONDITIONING (PSYCHOLOGY); CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; NALTREXONE; NARCOTIC ANTAGONISTS; NEURONS; NUCLEUS ACCUMBENS; POINT MUTATION; RATS; RECEPTORS, OPIOID, KAPPA; REWARD; RNA, MESSENGER; SIMPLEXVIRUS;

ANIMALIA;

EID: 20644461933     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5397.2272     Document Type: Article

References (44)

1. E. J. Nestler and G. K. Aghajanian, Science 278, 58 (1997); G. F. Koob and M. Le Moal, ibid., p. 52.
2. E. J. Nestler and G. K. Aghajanian, Science 278, 58 (1997); G. F. Koob and M. Le Moal, ibid., p. 52.
3. R. Z. Terwilliger, D. Beitner-Johnson, K. A. Severino, S. M. Crain, E. J. Nestler, Brain Res. 548, 100 (1991); E. Unterwald, J. Fillmore, M. Kreek, Eur. J. Pharmacol. 318, 31 (1996).
4. R. Z. Terwilliger, D. Beitner-Johnson, K. A. Severino, S. M. Crain, E. J. Nestler, Brain Res. 548, 100 (1991); E. Unterwald, J. Fillmore, M. Kreek, Eur. J. Pharmacol. 318, 31 (1996).
5. M. C. Ritz, R. J. Lamb, S. R. Goldberg, M. J. Kuhar, Science 237, 1219 (1987).
6. W. A. Carlezon Jr., D. P. Devine, R. A. Wise, Psychopharmacology 122, 194 (1995).
7. D. W. Self et al., J. Neurosci. 18, 1848 (1998).
8. G. A. Gonzalez and M. R. Montminy, Cell 59, 675 (1989); J. C. Chrivia et al., Nature 365, 855 (1993); R. P. S. Kwok et al., ibid. 370, 223 (1994).
9. G. A. Gonzalez and M. R. Montminy, Cell 59, 675 (1989); J. C. Chrivia et al., Nature 365, 855 (1993); R. P. S. Kwok et al., ibid. 370, 223 (1994).
10. G. A. Gonzalez and M. R. Montminy, Cell 59, 675 (1989); J. C. Chrivia et al., Nature 365, 855 (1993); R. P. S. Kwok et al., ibid. 370, 223 (1994).
11. R. L. Cole, C. Konradi, J. Douglass, S. E. Hyman, Neuron 14, 813 (1995); S. M. Turgeon, A. E. Pollack, J. S. Fink, Brain Res. 749, 120 (1997).
12. R. L. Cole, C. Konradi, J. Douglass, S. E. Hyman, Neuron 14, 813 (1995); S. M. Turgeon, A. E. Pollack, J. S. Fink, Brain Res. 749, 120 (1997).
13. Rewarding drugs establish conditioned place preferences [G. D. Carr, H. C. Fibiger, A. G. Phillips, in The Neuropharmacological Basis of Reward, J. M. Liebman, and S. J. Cooper, Eds. (Oxford University Press, Oxford, 1989); R. A. Wise, ibid]. Place conditioning was conducted with ip cocaine in a three-compartment apparatus exactly as described in (72).
14. Rewarding drugs establish conditioned place preferences [G. D. Carr, H. C. Fibiger, A. G. Phillips, in The Neuropharmacological Basis of Reward, J. M. Liebman, and S. J. Cooper, Eds. (Oxford University Press, Oxford, 1989); R. A. Wise, ibid]. Place conditioning was conducted with ip cocaine in a three-compartment apparatus exactly as described in (72).
15. Bilateral microinjections (2.0 μl) of HSV vectors were delivered over 10 min into the nucleus accumbens shell (relative to bregma: AP = +1.7, lat = ±2.3, DV = 6.8 mm below dura) or core (AP = +1.7, lat = ±3.9, DV = 6.5 mm below dura) [G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates (Academic, Sidney, 1986)] of anesthetized rats (325 to 375 g) as described in (12). The injection syringe was angled at 10° from the midline.
16. 7 infectious units per milliliter.
17. 7 infectious units per milliliter.
18. W. A. Carlezon Jr. and R. A. Wise, J. Neurosci. 16, 3112 (1996); R. C. Pierce and P. W. Kalivas, Brain Res. Rev. 25, 192 (1997).
19. W. A. Carlezon Jr. and R. A. Wise, J. Neurosci. 16, 3112 (1996); R. C. Pierce and P. W. Kalivas, Brain Res. Rev. 25, 192 (1997).
20. W. A. Carlezon Jr. et al., Science 277, 812 (1997).
21. β-Calactosidase expression was examined as described [N. Min, T. H. Joh, K. S. Kim, C. Peng, J. H. Son, Mol. Brain Res. 27, 281 (1994)]. Immunohistochemical analysis for CREB and mCREB was similar to that described in (12); slices were incubated with an antibody to CREB (1:1000; Upstate Biotechnology), biotinylated goat antibody to rabbit immunoglobulin G (IgG) (1:200; Vector Laboratories), and avidin-biotin (ABC Elite; Vector). The blocking solution was 1% bovine serum albumin containing 2% normal goat serum.
22. C. Chavkin, I. F. James, A. Goldstein, Science 215, 413 (1982).
23. Y. L. Hurd, E. E. Brown, J. M. Finlay, H. C. Fibiger, C. R. Gerfen, Mol. Brain Res. 13, 165 (1992); R. Spangler, E. M. Unterwald, M. J. Kreek, ibid. 19, 323 (1993); J. B. Daunais, D. C. S. Roberts, J. F. McGinty, Neuroreport 4, 453 (1993).
24. Y. L. Hurd, E. E. Brown, J. M. Finlay, H. C. Fibiger, C. R. Gerfen, Mol. Brain Res. 13, 165 (1992); R. Spangler, E. M. Unterwald, M. J. Kreek, ibid. 19, 323 (1993); J. B. Daunais, D. C. S. Roberts, J. F. McGinty, Neuroreport 4, 453 (1993).
25. Y. L. Hurd, E. E. Brown, J. M. Finlay, H. C. Fibiger, C. R. Gerfen, Mol. Brain Res. 13, 165 (1992); R. Spangler, E. M. Unterwald, M. J. Kreek, ibid. 19, 323 (1993); J. B. Daunais, D. C. S. Roberts, J. F. McGinty, Neuroreport 4, 453 (1993).
26. R. Bals-Kubik, A. Albleitner, A. Herz, T. S. Shippenberg, J. Pharmacol. Exp. Ther. 264, 489 (1993).
27. 32P-labeled RNA probe (provided by C. R. Gerfen, National Institute of Mental Health) as described [M. Nibuya, S. Morinobu, R. S. Duman, J. Neurosci. 15, 7539 (1995)].
28. norBNI (5.0 μg) was administered intracerebroventricutarly (relative to bregma, AP = -0.3, lat = +1.2, DV = 4.0 mm below dura) in 2.0 μl of physiological saline over 10 min immediately before gene transfer; the drug blocks κ opioid receptors for more than 3 weeks in rats [R. Spanagel and T. S. Shippenberg, Neurosci. Lett. 153, 232 (1993)].
29. H. Steiner and C. R. Gerfen, J. Comp. Neurol. 353, 200 (1995); S. Hyman, Neuron 16, 901 (1996); T. S. Shippenberg and W. Rea, Pharmacol. Biochem. Behav. 57, 449 (1997).
30. H. Steiner and C. R. Gerfen, J. Comp. Neurol. 353, 200 (1995); S. Hyman, Neuron 16, 901 (1996); T. S. Shippenberg and W. Rea, Pharmacol. Biochem. Behav. 57, 449 (1997).
31. H. Steiner and C. R. Gerfen, J. Comp. Neurol. 353, 200 (1995); S. Hyman, Neuron 16, 901 (1996); T. S. Shippenberg and W. Rea, Pharmacol. Biochem. Behav. 57, 449 (1997).
32. C. DiChiara and A. Imperato, J. Pharmacol. Exp. Ther. 244, 1067 (1988); R. Spanagel, A. Herz, T. S. Shippenberg, J. Neurochem. 55, 1734 (1990).
33. C. DiChiara and A. Imperato, J. Pharmacol. Exp. Ther. 244, 1067 (1988); R. Spanagel, A. Herz, T. S. Shippenberg, J. Neurochem. 55, 1734 (1990).
34. T. S. Shippenberg, R. Bals-Kubik, A. Huber, A. Herz, Psychopharmcology 103, 209 (1991); E. A. Loh and D. C. S. Roberts, ibid. 101, 262 (1990); N. R. Richardson and D. C. S. Roberts, Life Sci. 49, 833 (1991).
35. T. S. Shippenberg, R. Bals-Kubik, A. Huber, A. Herz, Psychopharmcology 103, 209 (1991); E. A. Loh and D. C. S. Roberts, ibid. 101, 262 (1990); N. R. Richardson and D. C. S. Roberts, Life Sci. 49, 833 (1991).
36. T. S. Shippenberg, R. Bals-Kubik, A. Huber, A. Herz, Psychopharmcology 103, 209 (1991); E. A. Loh and D. C. S. Roberts, ibid. 101, 262 (1990); N. R. Richardson and D. C. S. Roberts, Life Sci. 49, 833 (1991).
37. E. Bartlett, A. Hallin, B. Chapman, B. Angrist, Neuropsychopharmacology 16, 77 (1997); J. H. Mendelson, M. Scholar, N. K. Mello, S. K. Teoh, J. W. Sholar, ibid. 18, 263 (1998).
38. E. Bartlett, A. Hallin, B. Chapman, B. Angrist, Neuropsychopharmacology 16, 77 (1997); J. H. Mendelson, M. Scholar, N. K. Mello, S. K. Teoh, J. W. Sholar, ibid. 18, 263 (1998).
39. Y. L. Hurd and M. Herkenham, Synapse 13, 357 (1993).
40. L. W. Fitzgerald, J. Ortiz, A. G. Hamedani, E. J. Nestler, J. Neurosci. 16, 274 (1996); X.-F. Zhang, X-T. Hu, F. J. White, M. E. Wolf, J. Pharmacol. Exp. Ther. 281, 699 (1997).
41. L. W. Fitzgerald, J. Ortiz, A. G. Hamedani, E. J. Nestler, J. Neurosci. 16, 274 (1996); X.-F. Zhang, X-T. Hu, F. J. White, M. E. Wolf, J. Pharmacol. Exp. Ther. 281, 699 (1997).
42. B. T. Lett, Psychopharmacology 98, 357 (1989); T. E. Robinson and K. C. Berridge, Brain Res. Rev. 18, 247 (1993).
43. B. T. Lett, Psychopharmacology 98, 357 (1989); T. E. Robinson and K. C. Berridge, Brain Res. Rev. 18, 247 (1993).
44. Supported by grants (to E.J.N.) and a fellowship (to W.A.C.) from the National Institute on Drug Abuse and a grant (to R.L.N.) from the National Institute of Child Health and Human Development.